Ye, Liu-Fang
65384  results:
Search for persons X
?
1

Clinical and molecular characteristics of RNF43 mutations a..:

Huang, Zi-Yao ; Wen, Lei ; Ye, Liu-Fang...
Therapeutic Advances in Medical Oncology.  16 (2024)  - p. , 2024
 
?
2

ASO Visual Abstract: Circulating Lipid- and Inflammation-Ba..:

Bai, Long ; Yan, Xiao-Luan ; Lu, Yun-Xin...
Annals of Surgical Oncology.  29 (2022)  7 - p. 4324-4325 , 2022
 
?
4

Circulating Lipid- and Inflammation-Based Risk (CLIR) Score..:

Bai, Long ; Yan, Xiao-Luan ; Lu, Yun-Xin...
Annals of Surgical Oncology.  29 (2022)  7 - p. 4308-4323 , 2022
 
?
7

Efficacy and safety of modified FOLFIRINOX as salvage thera..:

Ye, Liu-Fang ; Ren, Chao ; Bai, Long...
Investigational New Drugs.  39 (2021)  3 - p. 836-845 , 2021
 
?
9

The first Mn–Zn heterometallic dinuclear compound based on ..:

Chen, Yue-Nan ; Ge, Ying-Ying ; Zhou, Wei...
Inorganic Chemistry Communications.  14 (2011)  8 - p. 1228-1232 , 2011
 
?
10

Clinical and molecular characteristics of RNF43 mutations a..:

Huang, Zi-Yao ; Wen, Lei ; Ye, Liu-Fang...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10777808/.  , 2024
 
?
12

Heterogeneity and evolution of tumour immune microenvironme..:

Wang, Wei ; Ye, Liu-Fang ; Bao, Hua...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587966/.  , 2022
 
?
13

Circulating Lipid- and Inflammation-Based Risk (CLIR) Score..:

Bai, Long ; Yan, Xiao-Luan ; Lu, Yun-Xin...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174322/.  , 2022
 
?
14

The Prognostic Value of Locoregional Interventions for BRAF..:

Ye, Liu-Fang ; Ji, Xiao-Meng ; Ren, Chao...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468777/.  , 2021
 
?
 
1-15